title: Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
abstract: Intravenous antiarrhythmic drugs will continue to have an important role in the acute management of SVT. Long-term antiarrhythmic drug therapy is often effective in preventing or reducing frequency and severity of arrhythmic episodes. The cost, adverse effects, and inconvenience of long-term drug therapy will result in the increasing use of curative ablation for most individuals with problematic SVT.
authors.affiliation: Division of Cardiology, University of Western Ontario, London, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Basta
authors.forename: G J
authors.initials: GJ
authors.lastname: Klein
authors.forename: R
authors.initials: R
authors.lastname: Yee
authors.forename: A
authors.initials: A
authors.lastname: Krahn
authors.forename: J
authors.initials: J
authors.lastname: Lee
mesh_terms: D000241:Adenosine / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001282:Atrial Flutter / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D004562:Electrocardiography; D006801:Humans; D026902:Potassium Channel Blockers; D013015:Sotalol / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D026902:Potassium Channel Blockers; D004077:Digoxin; D013015:Sotalol; D000241:Adenosine; D000638:Amiodarone